Kinarus Therapeutics Holding AG KNRS

SWX: KNRS | ISIN: CH0009115129   17/05/2024
8,295 CHF (+1,78%)
(+1,78%)   17/05/2024

12 juli 2023 · Kinarus Therapeutics Announces Personnel Change · Persbericht

29 juni 2023 · Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting · Persbericht

27 juni 2023 · Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity · Persbericht

2 juni 2023 · Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting · Persbericht

31 mei 2023 · Kinarus Therapeutics Group Reports 2022 Annual Results · Persbericht

11 mei 2023 · Kinarus Therapeutics signed CHF1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management · Persbericht

5 mei 2023 · Kinarus Therapeutics Reports Key Unaudited Full Year 2022 Figures · Persbericht

28 april 2023 · Kinarus Therapeutics Holding AG ("Kinarus") receives deadline extension from SER for publication of its 2022 annual financial report · Persbericht

21 februari 2023 · Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update · Persbericht

17 januari 2023 · Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan · Persbericht

6 december 2022 · Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5 · Persbericht

22 november 2022 · Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001 · Persbericht

16 november 2022 · Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China · Persbericht

4 november 2022 · Kinarus Therapeutics Provides Strategic Update · Persbericht

30 september 2022 · Kinarus Therapeutics Announces Discontinuation of the Phase 2 KINETIC Study of KIN001 in Hospitalized COVID-19 Patients Following a Prespecified Interim Analysis of Efficacy and Safety · Persbericht

22 augustus 2022 · Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19 · Persbericht

22 augustus 2022 · Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville · Persbericht

Mijn selecties